Compare SPDR Gold Trust (GLD) vs Novo Nordisk A/S (NVO) Price & Performance

SPDR Gold TrustTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

SPDR Gold Trust vs Novo Nordisk A/S — how do they compare? SPDR Gold Trust trades at $404.91, while Novo Nordisk A/S trades at $46.19 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while SPDR Gold Trust pays none, and SPDR Gold Trust is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.

	GLD	NVO
52-Week High	$495.90	$63.98
52-Week Low	$305.27	$35.29
Market Cap	—	$207.85B
Sector	—	Health
Enterprise Value	—	$222.55B
Dividend Yield	—	3.81%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

SPDR Gold Trust

GLD, the SPDR Gold Shares ETF, trades at $405.25, up 0.65% today, reflecting strong momentum as gold benefits from cooling U.S. inflation data and safe-haven demand. The technical outlook is bullish with moving averages supporting upward trends, though oscillators signal overbought conditions. Recent news highlights gold's resilience amid geopolitical tensions and central bank buying, with spot gold surpassing $4,438 per ounce after July's CPI report showed a 2.5% annual core increase (Kitco, 2026-08-12).

The outlook for GLD remains positive driven by macroeconomic support, but risks include potential Fed policy shifts and profit-taking pressure. Investors may see opportunities in gold's role as a hedge, though high RSI levels suggest near-term volatility. Key resistance at $407 could test further gains, while support lies at $396.

Novo Nordisk A/S

NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.

The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GLD

Citadel Securities sees strong upside for gold and silver in 2026 amid dovish Fed and rising demand.Kitco · 2 days agoBullish Gold jumps 7% on weaker dollar, lower yields, and softer US jobs data, signaling potential breakout.CNBC · 2 days agoBullish New gold ETF offers income via options, challenging traditional GLD's no-yield hold amid gold's flat run.24/7 Wall Street · 4 days agoNeutral View details →

NVO

Novo Nordisk stays a Buy with strong obesity drug lead and improved 2026 outlook despite near-term challenges.Seeking Alpha · 5 hours agoBullish Novo Nordisk faces sell rating amid rising competition and operational challenges, with price target cut to $47.Alex Lavoie · 6 hours agoBearish View details →

About SPDR Gold Trust

GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.